RBM20 Regulates Circular RNA Production From the Titin Gene.

Circ Res

From the Department of Experimental Cardiology (M.A.F.K., Y.J.R., S.A., M.M.G.v.d.H., I.v.d.M., A.B., E.E.C., Y.M.P.), Department of Clinical Epidemiology, Biostatistics and Bioinformatics (M.A.F.K., S.A.), and Department of Cardiothoracic Surgery (D.R.K.), Academic Medical Center, Amsterdam, The Netherlands; Department of Cardiology, Aarhus University Hospital, Denmark (T.B.R.); and Department of Physiology, VU University Medical Center, Amsterdam, The Netherlands (J.v.d.V.).

Published: October 2016

AI Article Synopsis

  • RBM20 is vital for splicing cardiac genes and its deficiency leads to dilated cardiomyopathy, raising the question of its role in the formation of circular RNAs (circRNAs) in the heart.
  • Researchers profiled circRNAs in human hearts and found thousands, with 80 being specifically linked to the titin gene, highlighting their regulation in dilated but not hypertrophic cardiomyopathy.
  • The study demonstrated that RBM20-null mice lacked these titin circRNAs, and RBM20 mutation in cardiac samples led to significant alterations in circRNA production, indicating RBM20's specific influence on certain circRNAs generated from the I-band region of the titin gene.

Article Abstract

Rationale: RNA-binding motif protein 20 (RBM20) is essential for normal splicing of many cardiac genes, and loss of RBM20 causes dilated cardiomyopathy. Given its role in splicing, we hypothesized an important role for RBM20 in forming circular RNAs (circRNAs), a novel class of noncoding RNA molecules.

Objective: To establish the role of RBM20 in the formation of circRNAs in the heart.

Methods And Results: Here, we performed circRNA profiling on ribosomal depleted RNA from human hearts and identified the expression of thousands of circRNAs, with some of them regulated in disease. Interestingly, we identified 80 circRNAs to be expressed from the titin gene, a gene that is known to undergo highly complex alternative splicing. We show that some of these circRNAs are dynamically regulated in dilated cardiomyopathy but not in hypertrophic cardiomyopathy. We generated RBM20-null mice and show that they completely lack these titin circRNAs. In addition, in a cardiac sample from an RBM20 mutation carrier, titin circRNA production was severely altered. Interestingly, the loss of RBM20 caused only a specific subset of titin circRNAs to be lost. These circRNAs originated from the RBM20-regulated I-band region of the titin transcript.

Conclusions: We show that RBM20 is crucial for the formation of a subset of circRNAs that originate from the I-band of the titin gene. We propose that RBM20, by excluding specific exons from the pre-mRNA, provides the substrate to form this class of RBM20-dependent circRNAs.

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCRESAHA.116.309568DOI Listing

Publication Analysis

Top Keywords

titin gene
12
circrnas
10
rbm20
9
loss rbm20
8
dilated cardiomyopathy
8
role rbm20
8
titin circrnas
8
titin
7
rbm20 regulates
4
regulates circular
4

Similar Publications

Background: Protein-truncating mutations in the titin gene are associated with increased risk of atrial fibrillation. However, little is known about the underlying pathophysiology.

Methods: We identified a heterozygous titin truncating variant (TTNtv) in a patient with unexplained early onset atrial fibrillation and normal ventricular function.

View Article and Find Full Text PDF

-Related Muscular Dystrophies, LGMD, and TMD, in an Estonian Family Caused by the Finnish Founder Variant.

Neurol Genet

December 2024

From the The Institute of Clinical Medicine (K.Õ., T.R., E.Õ.-S., L.M., S. Pajusalu), Faculty of Medicine, University of Tartu; Genetics and Personalized Medicine Clinic (K.Õ., T.R., L.M., Sander Pajusalu); Children's Clinic (E.O.-S.); Pathology Department (S. Puusepp), Tartu University Hospital, Estonia; Folkhalsan Research Center (M.S., B.U.), Helsinki; and Tampere Neuromuscular Center (B.U.), Tampere, Finland.

Background And Objectives: Tibial muscular dystrophy (TMD) is an autosomal dominant, slowly progressive late-onset distal myopathy. TMD was first described in 1991 by Udd et al. in Finnish patients, who were later found to harbor a heterozygous unique 11-bp insertion/deletion in the last exon of the gene-the Finnish founder variant (FINmaj).

View Article and Find Full Text PDF

Titin fragment is a sensitive biomarker in Duchenne muscular dystrophy model mice carrying full-length human dystrophin gene on human artificial chromosome.

Sci Rep

January 2025

Department of Chromosome Biomedical Engineering, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori, 683‑8503, Japan.

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations of the dystrophin gene, which spans 2.4 Mb on the X chromosome. Creatine kinase (CK) activity in blood and titin fragment levels in urine have been identified as biomarkers in DMD to monitor disease progression and evaluate therapeutic intervention.

View Article and Find Full Text PDF

Duchenne muscular dystrophy (DMD) is a severe muscle disorder caused by mutations in the DMD gene, leading to dystrophin deficiency. Antisense oligonucleotide (ASO)-mediated exon skipping offers potential by partially restoring dystrophin, though current therapies remain mutation specific with limited efficacy. To overcome those limitations, we developed brogidirsen, a dual-targeting ASO composed of two directly connected 12-mer sequences targeting exon 44 using phosphorodiamidate morpholino oligomers.

View Article and Find Full Text PDF

Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies.

Egypt Heart J

January 2025

Department of Physiology, Faculty of Basic Medical Sciences, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu Campus, Sagamu, Ogun State, Nigeria.

Background: Hypertrophic cardiomyopathy (HCM) is a frequently encountered cardiac condition worldwide, often inherited, and characterized by intricate phenotypic and genetic manifestations. The natural progression of HCM is diverse, largely due to mutations in the contractile and relaxation proteins of the heart. These mutations disrupt the normal structure and functioning of the heart muscle, particularly affecting genes that encode proteins involved in the contraction and relaxation of cardiac muscle.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!